Armstrong Fleming & Moore Inc Acquires New Holdings in Pfizer Inc. $PFE

Armstrong Fleming & Moore Inc acquired a new stake in Pfizer Inc. (NYSE:PFE) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 9,855 shares of the biopharmaceutical company’s stock, valued at approximately $239,000.

A number of other large investors have also added to or reduced their stakes in the business. Tectonic Advisors LLC raised its holdings in Pfizer by 22.1% in the 2nd quarter. Tectonic Advisors LLC now owns 298,687 shares of the biopharmaceutical company’s stock valued at $7,240,000 after buying an additional 54,068 shares during the last quarter. Cohen Investment Advisors LLC raised its holdings in Pfizer by 16.9% during the 2nd quarter. Cohen Investment Advisors LLC now owns 103,490 shares of the biopharmaceutical company’s stock worth $2,509,000 after purchasing an additional 14,984 shares during the last quarter. Vontobel Holding Ltd. raised its holdings in Pfizer by 2.1% during the 2nd quarter. Vontobel Holding Ltd. now owns 736,235 shares of the biopharmaceutical company’s stock worth $17,846,000 after purchasing an additional 14,808 shares during the last quarter. Maryland State Retirement & Pension System raised its holdings in Pfizer by 4.1% during the 2nd quarter. Maryland State Retirement & Pension System now owns 276,125 shares of the biopharmaceutical company’s stock worth $6,693,000 after purchasing an additional 10,986 shares during the last quarter. Finally, PARK CIRCLE Co raised its holdings in Pfizer by 374.4% during the 2nd quarter. PARK CIRCLE Co now owns 83,500 shares of the biopharmaceutical company’s stock worth $2,024,000 after purchasing an additional 65,900 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE opened at $25.67 on Thursday. The firm’s fifty day moving average price is $24.79 and its two-hundred day moving average price is $24.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $145.95 billion, a price-to-earnings ratio of 13.65, a P/E/G ratio of 0.86 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PFE has been the subject of several analyst reports. Citigroup raised their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Finally, Bank of America lifted their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.